| Company Name: | 3SBio, Incorporated Sponsored American Deposit Receipt Representing 7 Shares | | Ticker Symbol: | SSRX | | | WWW Address: | www.3sbio.com | | CEO: | Dr. Jing Lou, Ph.D. | | No. of Employees: | 483 | | Common Issue Type: | AD | | Business Description: | A biotechnology company, which focuses on researching, developing, manufacturing and marketing of biopharmaceutical products mainly in China.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 13.42 |  0.59 | 13.42 | 13.47 | 12.86 | 13.01 | 12.19 | 137708 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 288.5 | 21.5 | 2.08 | 0.27 | 0.00 | 8.3 | 0.0 | 13.01 - 4.18 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 12.83 | $ | | PE Ratio - LTM | 8.3 | |
| Market Capitalisation | 276.0 | mil |
| Latest Shares Outstanding | 21.5 | mil |
| Earnings pS (EPS) | 0.27 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 73,812 | $ |
| Effective Tax Rate | 23.0 | % |
| Float | 0.0 | mil |
| Float as % of Shares Outstanding | 0.0 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 34 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 59.80 | % |
| Research & Devlopment (R&D) as % of Revenue | 8.40 | % |
| Gross Profit Margin | 91.9 | % |
| EBITDA Margin | 23.7 | % |
| Pre-Tax Profit Margin | 19.9 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | 4.3 | % |
| Return on Equity (ROE) | 4.5 | % |
| Return on Capital Invested (ROCI) | 4.5 | % |
| Current Ratio | 25.8 | |
| Leverage Ratio (Assets/Equity) | 1.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 5.69 | $ |
| Cash pS | 1.21 | $ |
| Book-Value pS | 6.58 | $ |
| Tangible Book-Value pS | 6.55 | $ |
| Cash Flow pS | 0.30 | $ |
| Free Cash Flow pS | 0.12 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.95 | |
| Price/Tangible Book Ratio | 1.96 | |
| Price/Cash Flow | 42.3 | |
| Price/Free Cash Flow | 103.5 | |
| P/E as % of Industry Group | 38.0 | % |
| P/E as % of Sector Segment | 6.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 13.6 | 114 | 1,120 | 6,460 |
| 4 Weeks | 13.01 | 9.72 | 11.38 | 12.7 | 112 | 980 | 19,593 |
| 13 Weeks | 13.01 | 9.56 | 9.96 | 28.8 | 121 | 911 | 58,289 |
| 26 Weeks | 13.01 | 7.06 | 8.22 | 56.1 | 127 | 752 | 95,510 |
| 52 Weeks | 13.01 | 4.18 | 5.02 | 155.6 | 187 | 688 | 172,593 |
| YTD | 13.01 | 4.18 | - | 64.5 | 136 | 706 | 158,953 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 12.17 | 11.70 | 11.05 | 9.57 | 8.62 | 2.08 | 2.08 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 54.36 | 89.9 | 73.43 |
| Income | 165.70 | 84.8 | 75.15 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 93.02 |
| R&D | 0.00 | NA | 81.45 |
| Normalized Inc. | 0.00 | NA | 55.24 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 799.4 | 822.2 | 44.3 |
| Earnings % | 1056.0 | 9689.5 | -48.1 |
| EPS % | 1050.0 | 12500.0 | -50.6 |
| EPS $ | 2.94 | 1.25 | -0.27 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 83.50 |
| Current Ratio | 28.5 |
| Quick Ratio (Acid Test) | 27.9 |
| Liquidity Ratio (Cash) | 25.36 |
| Receivables Turnover | 3.9 |
| Average Collection Period | 92 |
| Working Capital/Equity | 86.5 |
| Working Capital pS | 5.42 |
| Cash-Flow pS | 0.31 |
| Free Cash-Flow pS | 0.12 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 36.28 |
| Financial Leverage Ratio (Assets/Equity) | 1.0 |
| Debt Ratio | 3.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 0.4 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.38 |
| Tobin's Q Ratio | 1.98 |
| Current P/E Ratio - LTM | 8.30 |
| Enterprise Value (EV)/EBITDA | 21.97 |
| Enterprise Value (EV)/Free Cash Flow | 76.59 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 1.96 |
| Price/Book Ratio - LTM | 1.95 |
| Price/Cash Flow Ratio | 42.3 |
| Price/Free Cash Flow Ratio - LTM | 103.5 |
| Price/Sales Ratio | 2.24 |
| P/E Ratio (1 month ago) - LTM | 8.0 |
| P/E Ratio (26 weeks ago) - LTM | 34.3 |
| P/E Ratio (52 weeks ago) - LTM | 12.6 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 38.0 |
| P/E as % of Sector Segment | 6.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 43.7 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.20 |
| Tangible Book Value pS - LTM | 6.55 |
| Book Value pS - LTM | 6.58 |
| Capital Invested pS | 6.27 |
| Cash pS - LTM | 1.21 |
| Cash Flow pS - LTM | 0.30 |
| Free Cash Flow pS - LTM | 0.12 |
| Earnings pS (EPS) | 0.27 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 7.48 |
| Free Cash Flow Margin 5YEAR AVG | 17.92 |
| Net Profit Margin | 16.3 |
| Net Profit Margin - 5YEAR AVRG. | 24.0 |
| Equity Productivity | 0.26 |
| Return on Equity (ROE) | 4.3 |
| Return on Equity (ROE) - 5YEAR AVRG. | 8.4 |
| Capital Invested Productivity | 0.26 |
| Return on Capital Invested (ROCI) | 4.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 8.2 |
| Assets Productivity | 0.30 |
| Return on Assets (ROA) | 4.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 7.2 |
| Gross Profit Margin | 91.9 |
| Gross Profit Margin - 5YEAR AVRG. | 93.0 |
| EBITDA Margin - LTM | 23.7 |
| EBIT Margin - LTM | 19.9 |
| Pre-Tax Profit Margin | 20.8 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 27.0 |
| Effective Tax Rate | 23.0 |
| Effective Tax Rate - 5YEAR AVRG. | 11.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 271 |
| Revenue per Employee | 73,812 |
| Net Income per Employee | 11,998 |
| Average Collection Period | 109 |
| Receivables Turnover | 3.9 |
| Day's Inventory Turnover Ratio | 162 |
| Inventory Turnover | 2.2 |
| Inventory/Sales | 3.2 |
| Accounts Payble/Sales | 0.80 |
| Assets/Revenue | 3.33 |
| Net Working Capital Turnover | 0.31 |
| Fixed Assets Turnover | 1.90 |
| Total Assets Turnover | 0.3 |
| Revenue per $ Cash | 0.55 |
| Revenue per $ Plant | 3.11 |
| Revenue per $ Common Equity | 0.26 |
| Revenue per $ Capital Invested | 0.26 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 62.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 60.6 |
| Research & Devlopment (R&D) as % of Revenue | 9.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 9.2 |
|
|  
|
| |
 |  |